ANN ARBOR, Mich. – February 2, 2015Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that Bruce A. Goldsmith, Ph.D., Chief Business Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015, at 11:15 a.m. Eastern Time. The conference will be held at the Waldorf Astoria in New York, NY. Dr. Goldsmith will provide a corporate overview and business update, including anticipated key milestones for 2015, and will be available to participate in one-on-one meetings.

 

About Lycera

Lycera is a biopharmaceutical company advancing novel treatments for cancer and autoimmune diseases based on a proprietary portfolio of small molecules designed primarily to either suppress or activate the immune response. The Company’s world-class expertise in distinct, yet complementary, areas of research – immune metabolism, cell signaling and immune cell differentiation – has generated four wholly owned programs, including a lead product candidate to treat inflammatory bowel disease (LYC-30937) expected to enter clinical testing in the first half of 2015. In addition, Lycera has established two collaborations with partner Merck to discover, develop and commercialize small molecule therapies for autoimmune disorders. The Lycera leadership team possesses deep experience from drug discovery and development through commercialization and has established close relationships with renowned thought leaders and clinical researchers worldwide. Lead investors in Lycera include InterWest Partners, ARCH Venture Partners, Clarus Ventures and EDF Ventures.